The global clinical trial equipment and ancillary solutions market size is likely to be valued at US$4.5 billion in 2026 and is estimated to reach US$9.2 billion by 2033, growing at a CAGR of 10.8% during the forecast period from 2026 to 2033, driven by increasing adoption of decentralized and hybrid clinical trials and rising development of cell and gene therapies requiring specialized cold-chain logistics.

Increasing pharmaceutical companies' outsourcing of equipment sourcing to improve trial efficiency also supports growth.

Driver- Rising Adoption of Home-Based Clinical Studies

The rising use of decentralized and hybrid clinical trials is creating high demand for clinical trial equipment and ancillary solutions. Instead of asking participants to visit hospitals frequently, sponsors are delivering medical devices and trial supplies directly to their homes. This requires providers to manage equipment sourcing, installation, calibration, retrieval, and technical support across multiple locations. Home-use devices such as blood pressure monitors, ECG devices, pulse oximeters, and digital thermometers have become essential components of several modern studies.

The U.S. Food and Drug Administration (FDA) continues to encourage decentralized clinical trial approaches through its guidance on decentralized clinical trials, supporting the use of remote data collection and home-based assessments. Similarly, companies such as Medable and ICON have expanded decentralized trial services, further increasing demand for specialized ancillary logistics and equipment management.

Ongoing Expansion of Advanced Biologic Therapies

The steady growth of cell therapies, gene therapies, and other advanced biologics is increasing the demand for highly specialized clinical trial equipment. These therapies are extremely sensitive to temperature changes and require ultra-low-temperature freezers, validated shipping containers, continuous temperature monitoring devices, and qualified cold-chain logistics throughout the trial. Even minor temperature deviations can affect product quality and patient safety.

According to the U.S. FDA, several cell and gene therapies require storage at cryogenic or ultra-low temperatures to maintain product integrity. Companies are responding by expanding their capabilities. For example, Ancillare strengthened its cold-chain management services in 2025 by introducing improved temperature-controlled logistics with real-time shipment visibility to support advanced therapy clinical trials.

Restraint- Complex Supply Networks May Raise Operational Costs and Delay Trial Execution

Managing non-investigational supplies remains a key challenge for clinical trial equipment providers. Every study requires a different combination of laboratory equipment, refrigerators, centrifuges, PPE, packaging materials, and diagnostic devices, sourced from multiple manufacturers. Coordinating procurement, quality checks, warehousing, international shipping, customs clearance, and site-specific kitting adds significant operational complexity.

Delays in receiving even one critical item can postpone site activation or patient enrollment. The U.S. FDA has highlighted that supply chain disruptions continue to affect medical products and healthcare operations, emphasizing the importance of resilient logistics. Global transportation challenges and strict regulatory documentation further increase costs, making efficient inventory planning and supplier coordination a prominent challenge for ancillary solution providers.

Opportunity- Real-Time Equipment Monitoring to Improve Trial Efficiency and Product Safety

The use of Internet of Things (IoT) technology presents a key opportunity for clinical trial equipment providers. Smart sensors attached to medical equipment and shipping containers continuously monitor location, temperature, humidity, vibration, and operating status during transportation and storage. This helps sponsors identify problems immediately and reduce the risk of equipment failure or temperature excursions.

Such visibility is especially valuable for biologics and cell therapies that require strict environmental control. DHL Health Logistics and other clinical supply providers have expanded the use of real-time monitoring technologies in cold-chain shipments to improve supply chain visibility. Increasing regulatory focus on product integrity is expected to boost adoption of connected monitoring solutions across global clinical trials.

AI-Based Inventory Planning to Help Prevent Supply Shortages During Trials

Artificial intelligence is creating new opportunities by improving forecasting and inventory management across clinical trial supply chains. AI tools analyze enrollment rates, site activity, shipment history, and inventory levels to predict future equipment and supply requirements. This allows sponsors to replenish materials before shortages occur and reduces unnecessary overstocking. Better forecasting also lowers product waste, especially for short-shelf-life investigational materials.

Leading life sciences companies are now investing in AI-enabled supply chain solutions to improve operational planning. For example, Thermo Fisher Scientific continues to extend digital technologies across its clinical research services to strengthen inventory visibility and logistics planning. As clinical trials become more global and decentralized, predictive inventory management is anticipated to become a key competitive advantage for ancillary solution providers.

Offering Insights

The supply/logistics segment is predicted to lead with a share of approximately 37.7% in 2026, as every clinical trial depends on the timely and compliant delivery of investigational products, medical equipment, laboratory kits, and patient supplies. Modern trials often span multiple countries, requiring providers to manage customs clearance, warehousing, temperature-controlled transportation, depot management, and return logistics. This is especially important for biologics, vaccines, and cell and gene therapies, where strict temperature control is essential throughout the supply chain. Even a short temperature excursion can make a product unusable and delay the study.

The sourcing segment is estimated to be the fastest-growing over the forecast period, as clinical trials require a wide range of equipment and consumables that vary by protocol, country, and healthcare facility. Sponsors now prefer a single sourcing partner instead of managing multiple vendors for medical devices, laboratory instruments, refrigeration units, diagnostic kits, and personal protective equipment. Centralized sourcing simplifies procurement, improves quality control, and ensures that equipment meets local regulatory requirements before reaching trial sites. The shift toward decentralized clinical trials has further raised demand, as providers must source home-use devices such as blood pressure monitors, pulse oximeters, glucometers, and digital thermometers for participants.

Phase Insights

The phase III segment is anticipated to dominate with a share of nearly 54.2% in 2026, as it involves the largest number of patients, study sites, and participating countries. These trials generate the highest demand for ancillary equipment, logistics, and operational support. Large-scale Phase III studies require thousands of medical devices, laboratory kits, temperature-controlled shipping containers, freezers, centrifuges, and patient monitoring equipment to be distributed across hospitals and research centers. The demand for continuous resupply, equipment maintenance, and reverse logistics also increases significantly during this phase.

The Phase I segment is expected to remain in second place in 2026, as pharmaceutical and biotechnology companies are developing numerous novel therapies, primarily in oncology, rare diseases, cell therapy, gene therapy, and RNA-based medicines. These early-stage studies require highly specialized equipment to monitor patient safety and collect detailed clinical data. Advanced laboratory instruments, infusion systems, ECG monitors, wearable devices, and ultra-low-temperature storage solutions are commonly used in first-in-human studies. Governments are also supporting the quick development of unique medicines.

North America Clinical Trial Equipment and Ancillary Solutions Market Trends

North America is predicted to dominate globally in 2026 with a share of approximately 42.2%, as it conducts a large share of global clinical research and has a well-established network of pharmaceutical companies, biotechnology firms, CROs, and specialized logistics providers. The region also has strong regulatory support for modern trial models. The U.S. Food and Drug Administration (FDA) has issued guidance encouraging decentralized clinical trials, promoting the use of home-based medical devices, telehealth, and remote monitoring. This has increased demand for equipment sourcing, calibration, shipping, and retrieval services.

U.S. Clinical Trial Equipment and Ancillary Solutions Market Trends

In North America, the U.S. is expected to hold nearly 61.2% in 2026, owing to increasing investments in decentralized trials, precision medicine, and advanced biologics. Pharmaceutical companies are constantly using wearable devices, electronic patient-reported outcome tools, and home diagnostic equipment to improve patient participation. The FDA's finalized guidance on decentralized clinical trials has given sponsors greater confidence to adopt remote trial models. The country is also investing heavily in domestic clinical manufacturing and supply infrastructure.

Asia Pacific Clinical Trial Equipment and Ancillary Solutions Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026, with a share of nearly 30.6%, as pharmaceutical companies expand clinical trials into countries with diverse patient populations, improve healthcare infrastructure, and accelerate participant recruitment. Governments across the region are introducing reforms to make clinical research more attractive for global sponsors. At the same time, hospitals and research institutions are adopting digital health technologies that support decentralized and hybrid trials. This creates demand for equipment rental, temperature-controlled logistics, and remote monitoring devices.

China Clinical Trial Equipment and Ancillary Solutions Market Trends

China will likely lead Asia Pacific in 2026, with a share of around 35.4%, supported by ongoing improvements in its clinical research environment and growing investment in pharmaceutical innovation. The National Medical Products Administration (NMPA) has introduced regulatory reforms in recent years to accelerate drug development and adapt clinical trial standards to international practices. China has also become a prominent location for oncology, immunology, and cell therapy studies, all of which require specialized ancillary equipment and cold-chain logistics. According to the government's Healthy China 2030 strategy, the country continues to strengthen biomedical development and clinical research capacity.

Japan Clinical Trial Equipment and Ancillary Solutions Market Trends

In 2026, Japan is projected to account for approximately 29.1% of the Asia Pacific market, owing to its growing focus on regenerative medicine, advanced healthcare technologies, and high-quality clinical research. The country has established supportive regulations for regenerative therapies, encouraging companies to conduct innovative clinical studies. These trials require specialized storage systems, laboratory equipment, and highly controlled transportation services. Japan is also adopting decentralized clinical trial models through collaborations between hospitals, technology companies, and pharmaceutical manufacturers.

Europe Clinical Trial Equipment and Ancillary Solutions Market Trends

Europe will likely see decent growth over the forecast period, with a share of nearly 17.4% globally in 2026, due to its well-established pharmaceutical industry, superior research collaboration, and harmonized regulatory framework. The implementation of the Clinical Trials Regulation (EU) No. 536/2014 and the Clinical Trials Information System (CTIS) has simplified multinational clinical trial applications across European Union member states. This has encouraged sponsors to conduct studies across multiple countries, thereby increasing demand for centralized equipment sourcing and cross-border logistics. Europe is also expanding research in Advanced Therapy Medicinal Products (ATMPs), which require strict temperature control and validated shipping systems.

Germany Clinical Trial Equipment and Ancillary Solutions Market Trends

Germany is anticipated to hold a substantial regional share of approximately 38.2% in Europe in 2026, spurred by its advanced healthcare infrastructure, internationally recognized research institutions, and large pharmaceutical manufacturing base. The country hosts various multinational clinical trials in oncology, cardiovascular diseases, and rare disorders. Germany is also investing in digital health through initiatives that support electronic health records and digital clinical research. Companies operating in the country now require specialized ancillary providers capable of managing complex equipment installation, calibration, and cross-border cold-chain logistics. Germany’s expertise in biologics manufacturing and precision medicine further strengthens demand for advanced clinical trial equipment solutions.

U.K. Clinical Trial Equipment and Ancillary Solutions Market Trends

A share of around 27.3% is predicted to be held by the U.K. in 2026 in 2026, as the government continues to strengthen the country's clinical research network. The U.K. Clinical Research Delivery Plan, published by the Department of Health and Social Care and NHS England, aims to make the country one of the most efficient locations for commercial clinical trials. The National Health Service (NHS) provides access to integrated patient data and a well-established hospital network, making decentralized and hybrid studies easy to implement. The U.K. is also increasing investments in life sciences, genomics, and AI-enabled healthcare. These developments are pushing demand for equipment rental, remote monitoring devices, clinical logistics, and other ancillary solutions required for modern clinical trial operations.

The global clinical trial equipment and ancillary solutions market is moderately fragmented, with competition spread across specialized ancillary solution providers, global clinical logistics companies, CROs, and laboratory service companies. Companies such as Ancillare, Quipment, Marken, Myonex, Imperial Clinical Research Services, Thermo Fisher Scientific, and Parexel are expanding bundled offerings that combine sourcing, equipment rental, packaging, temperature-controlled shipping, installation, calibration, retrieval, and reverse logistics under a single contract.

Another defining feature of competition is the race to support decentralized and hybrid clinical trials. Providers are investing in direct-to-patient equipment delivery, home nursing support, remote monitoring devices, wearable technologies, and digital inventory tracking. Equipment suppliers capable of delivering calibrated devices directly to participants while maintaining regulatory documentation are gaining preference from pharmaceutical companies conducting global hybrid studies.

Key Industry Developments:

• In May 2026, Roche announced a definitive merger agreement to acquire PathAI for US$750 million upfront and up to US$300 million in milestone payments. The companies stated that combining PathAI's AI-based pathology platform with Roche's companion diagnostics expertise would accelerate biomarker discovery, support clinical trial development, and advance AI-enabled precision medicine.
• In October 2025, Thermo Fisher Scientific announced an agreement to acquire Clario Holdings for approximately US$8.88 billion. Clario is a leading provider of endpoint data collection and clinical trial technology solutions. The acquisition broadens Thermo Fisher's clinical research services portfolio by integrating imaging, cardiac safety, digital biomarker, and electronic clinical outcome assessment capabilities.
• In July 2025, Thermo Fisher Scientific acquired a sterile fill-finish and packaging facility from Sanofi in Ridgefield, New Jersey. The acquisition expanded Thermo Fisher's U.S. clinical and commercial drug manufacturing and packaging capabilities, strengthening end-to-end support for pharmaceutical development and clinical supply operations.